Home › Funds › Casdin Capital › FATE
Casdin Capital position in FATE
FATE THERAPEUTICS INC · Health Care
Latest position (Q4 2023)2.05M sh
Reported value held$7.67M
Portfolio Weight0.75%
First reportedQ3 2021
Last changeHold
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 3.40M | $201.52M | New |
| Q4 2021 | 3.40M | $198.93M | Hold |
| Q1 2022 | 3.40M | $131.82M | Hold |
| Q2 2022 | 2.10M | $52.04M | Reduce |
| Q3 2022 | 2.05M | $45.94M | Reduce |
| Q4 2022 | 2.05M | $20.68M | Hold |
| Q1 2023 | 2.05M | $11.69M | Hold |
| Q2 2023 | 2.05M | $9.76M | Hold |
| Q3 2023 | 2.05M | $4.35M | Hold |
| Q4 2023 | 2.05M | $7.67M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding FATE
- BlackRock Inc 7.30M sh · $19.71M · Q2 2026
- AQR Capital Management 3.84M sh · $10.36M · Q2 2026
- Two Sigma Investments 3.59M sh · $9.69M · Q2 2026
- Vanguard Group 8.97M sh · $8.82M · Q4 2025
- Renaissance Technologies 2.98M sh · $8.05M · Q2 2026
- Millennium Management 2.43M sh · $6.57M · Q2 2026
- Goldman Sachs Group 2.05M sh · $5.53M · Q2 2026
- Geode Capital Management 1.32M sh · $3.57M · Q2 2026
- Citadel Advisors 1.09M sh · $2.95M · Q2 2026
- Morgan Stanley 694.58K sh · $1.88M · Q2 2026
- Charles Schwab Investment Management 610.95K sh · $1.65M · Q2 2026
- UBS Group AG 590.18K sh · $1.59M · Q2 2026